Literature DB >> 29624923

Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.

Sophia Karandashova1, Apparao Kummarapurugu2, Shuo Zheng2, Le Kang3, Shumei Sun3, Bruce K Rubin2, Judith A Voynow2.   

Abstract

INTRODUCTION: Sphingolipids are associated with the regulation of pulmonary inflammation. Although sphingolipids have been investigated in the context of cystic fibrosis (CF), the focus has been on loss of CF transmembrane conductance regulator (CFTR) function in mice, and in CF human lung epithelial cell lines. The sphingolipid content of CF sputum and the potential link between ceramide and airway inflammation in CF remain relatively unexplored.
METHODS: Fifteen patients with CF provided two spontaneously expectorated sputum samples, one collected during a hospitalization for an acute pulmonary exacerbation and one from an outpatient visit at a time of clinical stability. Sputum was processed, and the supernatant assessed for active neutrophil elastase (NE) using a chromogenic microplate assay and sphingolipid content using reverse phase high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). Relevant demographic data including age, sex, CF genotype, FEV1 % predicted, and sputum bacteriology were assessed as possible modifying factors that could influence the correlation between NE and sputum sphingolipids. Data were analyzed for linear correlation, with statistical significance pre-defined as P < 0.05.
RESULTS: There was a significant association between the concentration of active NE and ceramide, sphingomyelin, and monohexosylceramide moieties as well as sphingosine-1-phosphate. The presence of Methicillin-resistant Staphylococcus aureus (MRSA), FEV1 % predicted, and female gender further strengthened the association of NE and sphingolipids, but Pseudomonas aeruginosa had no effect on the association between NE and sphingolipids.
CONCLUSIONS: These data suggest that NE may increase pro-inflammatory sphingolipid signaling, and the association is strengthened in female patients and patients with MRSA.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ceramide; inflammation; lung disease

Mesh:

Substances:

Year:  2018        PMID: 29624923      PMCID: PMC6566867          DOI: 10.1002/ppul.24001

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  39 in total

1.  Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells.

Authors:  J A Voynow; L R Young; Y Wang; T Horger; M C Rose; B M Fischer
Journal:  Am J Physiol       Date:  1999-05

2.  Association between pulmonary function and sputum biomarkers in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Moira L Aitken; Frank J Accurso; Richard A Kronmal; Michael W Konstan; Jane L Burns; Scott D Sagel; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2007-01-18       Impact factor: 21.405

3.  Neutrophil elastase induces mucus cell metaplasia in mouse lung.

Authors:  Judith A Voynow; Bernard M Fischer; David E Malarkey; Lauranell H Burch; Teresa Wong; Malinda Longphre; Samuel B Ho; W Michael Foster
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-07-23       Impact factor: 5.464

4.  Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release.

Authors:  Benjamin J Pettus; Alicja Bielawska; Sarah Spiegel; Patrick Roddy; Yusuf A Hannun; Charles E Chalfant
Journal:  J Biol Chem       Date:  2003-07-10       Impact factor: 5.157

5.  Superoxide dismutase protects against apoptosis and alveolar enlargement induced by ceramide.

Authors:  Irina Petrache; Terry R Medler; Amy T Richter; Krzysztof Kamocki; Ugonma Chukwueke; Lijie Zhen; Yuan Gu; Jeremy Adamowicz; Kelly S Schweitzer; Walter C Hubbard; Evgeny V Berdyshev; Giuseppe Lungarella; Rubin M Tuder
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-25       Impact factor: 5.464

Review 6.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Am J Infect Control       Date:  2003-05       Impact factor: 2.918

7.  Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.

Authors:  Claudine Guilbault; Juan B De Sanctis; Gabriella Wojewodka; Zienab Saeed; Claude Lachance; Thomas A A Skinner; Regina M Vilela; Stan Kubow; Larry C Lands; Marian Hajduch; Elias Matouk; Danuta Radzioch
Journal:  Am J Respir Cell Mol Biol       Date:  2007-07-26       Impact factor: 6.914

8.  Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.

Authors:  Volker Teichgräber; Martina Ulrich; Nicole Endlich; Joachim Riethmüller; Barbara Wilker; Cheyla Conceição De Oliveira-Munding; Anna M van Heeckeren; Mark L Barr; Gabriele von Kürthy; Kurt W Schmid; Michael Weller; Burkhard Tümmler; Florian Lang; Heike Grassme; Gerd Döring; Erich Gulbins
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440

Review 9.  Proteases and cystic fibrosis.

Authors:  Judith A Voynow; Bernard M Fischer; Shuo Zheng
Journal:  Int J Biochem Cell Biol       Date:  2008-03-14       Impact factor: 5.085

10.  Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis.

Authors:  Olivier Gasser; Jürg A Schifferli
Journal:  Blood       Date:  2004-06-22       Impact factor: 22.113

View more
  3 in total

1.  Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis.

Authors:  Hamed Horati; Hettie M Janssens; Camilla Margaroli; Mieke Veltman; Marta Stolarczyk; Matthew B Kilgore; Jeffrey Chou; Limin Peng; Harm A M W Tiddens; Joshua D Chandler; Rabindra Tirouvanziam; Bob J Scholte
Journal:  J Cyst Fibros       Date:  2020-02-10       Impact factor: 5.482

Review 2.  Neutrophil Elastase and Chronic Lung Disease.

Authors:  Judith A Voynow; Meagan Shinbashi
Journal:  Biomolecules       Date:  2021-07-21

Review 3.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.